Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
The LancetPublished 1 August 2004
Helen M. Colhoun, D. J. Betteridge, Paul N. Durrington, G. A. Hitman, H. A. W. Neil, Shona Livingstone
Citations3,755
SJR quartileQ1
SJR score12.11
SNIP22.72
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Atorvastatin 10 mg daily is safe and efficacious in reducing the risk of first cardiovascular disease events, including stroke, in patients with type 2 diabetes without high LDL-cholesterol.
Abstract
Atorvastatin 10 mg daily is safe and efficacious in reducing the risk of first cardiovascular disease events, including stroke, in patients with type 2 diabetes without high LDL-cholesterol. No justification is available for having a particular threshold level of LDL-cholesterol as the sole arbiter of which patients with type 2 diabetes should receive statins. The debate about whether all people with this disorder warrant statin treatment should now focus on whether any patients are at sufficiently low risk for this treatment to be withheld.
Keywords
MedicineEconomics, Econometrics and Finance
Clinical ChemistryEstimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge
32,475 Citations1972William T. Friedewald, Robert I. Levy +1 more
A method for estimating the cholesterol content of the serum low-density lipoprotein fraction (Sf0-20) is presented and comparison of this suggested procedure with the more direct procedure, in which the ultracentrifuge is used, yielded correlation coefficients of .94 to .99.
The LancetMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
6,967 Citations2002S. Féasson
Adding simvastatin to existing treatments safely produces substantial additional benefits for a wide range of high-risk patients, irrespective of their initial cholesterol concentrations.
CirculationImplications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
6,928 Citations2004Scott M. Grundy, James I. Cleeman +7 more
The trials confirm the benefit of cholesterol-lowering therapy in high-risk patients and support the ATP III treatment goal of low-density lipoprotein cholesterol (LDL-C) <100 mg/dL, and confirm that older persons benefit from therapeutic lowering of LDL-C.
New England Journal of MedicinePrevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
5,299 Citations1998The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Pravastatin therapy reduced mortality from coronary heart disease and overall mortality, as compared with the rates in the placebo group, as well as the incidence of all prespecified cardiovascular events in patients with a history of myocardial infarction or unstable angina who had a broad range of initial cholesterol levels.
Diabetes CareDiabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial
4,098 Citations1993Jeremiah Stamler, Olga Vaccaro +2 more
Findings emphasize the need for rigorous sustained intervention in people with diabetes to control blood pressure, lower serum cholesterol, and abolish cigarette smoking, and the importance of considering nutritional-hygienic approaches on a mass scale to prevent diabetes.
The LancetPrevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
3,792 Citations2003Peter Sever, Björn Dahlöf +12 more
The LancetMRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial
2,899 Citations2003Rory Collins, Jane Armitage +3 more
Direct evidence is provided that cholesterol-lowering therapy is beneficial for people with diabetes even if they do not already have manifest coronary disease or high cholesterol concentrations and statin therapy should now be considered routinely for all diabetic patients at sufficiently high risk of major vascular events, irrespective of their initial cholesterol concentrations.
BMJRisk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23)
2,034 Citations1998R. C. Turner, Helen Millns +5 more
A quintet of potentially modifiable risk factors for coronary artery disease exists in patients with type 2 diabetes mellitus, which are increased concentrations of low density lipoprotein cholesterol, decreased concentrations of high density cholesterol, raised blood pressure, hyperglycaemia, and smoking.
Diabetes CareCholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
1,639 Citations1997Kalevi Pyörälà, Terje R. Pedersen +5 more
It is suggested that cholesterol lowering with simvastatin improves the prognosis of diabetic patients with CHD and the absolute clinical benefit achieved by cholesterol lowering may be greater in diabetic than in nondiabetic patients withCHD because diabetic patients have a higher absolute risk of recurrent CHD events and other atherosclerotic events.
JAMAPoor Control of Risk Factors for Vascular Disease Among Adults With Previously Diagnosed Diabetes
1,367 Citations2004Sharon Saydah
Participants with previously diagnosed diabetes in NHANES 1999-2000 were similar by age and sex, were less likely to be non-Hispanic white, were diagnosed at an earlier age, had a higher body mass index, and were more likely to use insulin in combination with oral agents.
Clinical ScienceThe UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
1,091 Citations2001Richard Stevens, Viti Kothari +2 more
The LancetEffects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions
1,064 Citations2004Rory Collins, Jane Armitage +3 more
The results demonstrate that statin therapy rapidly reduces the incidence not only of coronary events but also of ischaemic strokes, with no apparent effect on cerebral haemorrhage, even among individuals who do not have high cholesterol concentrations.
CirculationCardiovascular Events and Their Reduction With Pravastatin in Diabetic and Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol Levels
991 Citations1998Ronald Goldberg, Margot J. Mellies +8 more
Diabetic patients and nondiabetic patients with impaired fasting glucose are at high risk of recurrent coronary events that can be substantially reduced by pravastatin treatment.
BMJComparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies
394 Citations2002Josie Evans, Jixian Wang +1 more
International Journal of EpidemiologyCholesterol, coronary heart disease, and stroke in the Asia Pacific region
384 Citations2003Asia Pacific Cohort Studies Collaboration
In both Asian and non-Asian populations in the Asia-Pacific region, total cholesterol is similarly strongly associated with the risk of CHD and ischaemic, but not haemorrhagic, stroke.
CirculationPrinciples for National and Regional Guidelines on Cardiovascular Disease Prevention
382 Citations2004Sidney C. Smith, Rod Jackson +10 more
The recommendations in this report focus on clinical management of patients with established CVD and those at high risk; however, it is essential that each country include a societal approach to CVD prevention.
European Journal of Cardiovascular Prevention & RehabilitationEuropean guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts)
275 Citations2003Guy De Backer, Ettore Ambrosioni +19 more
Preamble Guidelines aim to present all the relevant evidence on a particular issue in order to help physicians to weigh the benefits and risks of a particular diagnostic or therapeutic procedure and be helpful in everyday clinical decision-making.
Clinical trial methodology
145 Citations2015R Peto, R Hamish McAllister-Williams
It was concluded that controlled clinical trials are required to answer comparative therapeutic questions in a convincing manner and that statistical advice is critical at all stages of such trials.
Journal of Clinical EpidemiologyStroke subtype and mortalitya follow-up study in 998 patients with a first cerebral infarct
144 Citations2003G DEJONG, L VANRAAK +2 more
Mortality following a first-ever cerebral infarct, accounting for ischemic stroke subtypes (lacunar, cardioembolic, atherothrombotic) and relevant prognostic variables was studied, with lacunar stroke patients having the lowest mortality.
The American Journal of CardiologyProtocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens
100 Citations1995Prepared by the Cholesterol Treatment Trialists' (CTT) Collaboration
By establishing a register of ongoing and planned trials prior to any trial results being known, this systematic overview attempts to avoid the methodologic problems and potential data-dependency of a retrospective project.
PubMedAlteration of cellular ribonucleases associated with murine oncogenic virus infection.
94 Citations1978Drake Wp, Frazier Lm +2 more
It is concluded that elevation of RNase activity within the lymphocyte represents an early event in oncogenic viral infection within these two tumor models.
Diabetic MedicineDesign of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes
93 Citations2002Helen M. Colhoun, Margaret J. Thomason +8 more
The design of a collaborative clinical trial between Diabetes UK, the NHS Research and Development Directorate and Pfizer UK, that addresses the role of lipid lowering in the primary prevention of coronary heart disease in diabetic patients is described.
StrokeIs Diabetes Mellitus a Cardiovascular Disease Risk Equivalent for Fatal Stroke in Women?
92 Citations2003Jennifer E. Ho, Furcy Paultre +1 more
Diabetic subjects without cardiovascular disease have a fatal stroke risk similar to that of nondiabetic subjects with a history of prior stroke and similar risk factor profile, which suggests that diabetes mellitus may be classified as a stroke risk equivalent and may warrant more aggressive treatment strategies in the future prevention of stroke.
Diabetes CareThe Impact of Diabetes on Survival Among Patients With First Myocardial Infarction
92 Citations1997Byung Yeol Chun, Annette J. Dobson +1 more
The increased risk of death in the diabetic patients remained after accounting for their poorer risk factor profiles; even if they reached the hospital alive, diabetic patients were also less likely to survive than nondiabetic patients; the relative impact of diabetes on survival is greater in women than in men.
HeartFactors determining case fatality in myocardial infarction "who dies in a heart attack"?
87 Citations1995S. Goya Wannamethee, Peter H. Whincup +3 more
It is suggested that physical activity may be an important modifiable factor influencing the incidence of ischaemic heart disease and the chance of survival in men without a previous heart attack or stroke.
Public HealthThe incidence and aetiology of stroke in the Caerphilly and Speedwell Collaborative Studies II
39 Citations2001Paul A. McCarron, Rosemary Greenwood +8 more
Multivariate analyses revealed that, while there was some attenuation of the effect of social class, angina and elevated BP, the risks from atrial fibrillation and diabetes were increased.
Public HealthThe incidence and aetiology of stroke in the Caerphilly and Speedwell Collaborative Studies II risk factors for ischaemic stroke
16 Citations2001P McCarron